Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives

Blood

Volumn 114, Issue 19, 2009, Pages 4272-4278

  Undas, Anetta ^a   Zawilska, Krystyna ^b   Ciesla Dul, Mariola ^c   Lehmann Kopydłowska, Agata ^b   Skubiszak, Agnieszka ^b   Ciepłuch, Katarzyna ^b   Tracz, Wiesława ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRIN; FIBRINOGEN;

ADULT; ARTICLE; BLOOD CLOT; BLOOD CLOTTING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PERMEABILITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENESIS; TURBIDIMETRY;

EID: 77949263452     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-222380     Document Type: Article

References (33)

1. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3(8):1611-1617.
2. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107[suppl 1]:I4-I8.
3. Chan MY, Andreotti F, Becker RC. Hypercoagulable states in cardiovascular disease. Circulation. 2008;118(22):2286-2297.
4. Reitsma PH, Rosendaal FR. Past and future of genetic research in thrombosis. J Thromb Haemost. 2007;5[suppl 1]:264-269.
5. Noboa S, Le Gal G, Lacut K, et al. Family history as a risk factor for venous thromboembolism. Thromb Res. 2008;122(5):624-629.
6. Scott EM, Ariëns RAS, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24(9):1558-1566.
7. Undas A, Szuldrzynski K, Stepien E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2007;196(2):551-558.
8. Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost. 1992;68(2):130-135.
9. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2567-2573.
10. Undas A, Podolec P, Zawilska K, et al. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischemic stroke. Stroke. 2009;40(4):1499-1501.
11. Curnow JL, Morel-Kopp MC, Roddie C, Aboud M, Ward CM. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost. 2007;5(3):528-534.
12. Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood. 2003;101(4):1243-1248.
13. Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3):1102-1105.
14. Mills JD, Ariëns RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation. 2002;106(15):1938-1942.
15. Undas A, Kolarz M, Kopeć G, Tracz W. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant. 2008;23(6):2010-2015.
16. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta. 1989;997(1):96-110.
17. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006;4(5):1029-1036.
18. Collet J-P, Mishal Z, Lesty C, et al. Abnormal fibrin clot architecture in nephritic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost. 1999;82(5):1482-1489.
19. Balogh I, Szôke G, Kárpáti L, et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood. 2000;96(7):2479-2486.
20. Carter AM, Catto AJ, Kohler HP, Ariëns RAS, Stickland MH, Grant PJ. Alpha fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood. 2000;96(3):1177-1179.
21. Wichers IM, Tanck MWT, Meijers JCM, et al. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thromb Haemost. 2009;101(3):465-470.
22. Prandoni P, Bilora F, Marchiori A, et al.An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348(15):1435-1441.
23. Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaarrd T, Stormer J, Hansen JB. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. J Thromb Haemost. 2008;6(11):1851- 1857.
24. Carter AM, Cymbalista CM, Spector TD, Grant PJ. Heritability of clot formation, morphology, and lysis: the EuroCLOT Study. Arterioscler Thromb Vasc Biol. 2007;27(12):2783-2789.
25. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol. 2006;26(6):1397-1404.
26. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007;21(3):131-142.
27. Tripodi A, Martinelli I, Chantaranqkul V, Battagliolo T, Clerici M, Mannucci PM. The endogenous thrombin potential and the risk of venous thromboembolism. Thromb Res. 2007;121(3):353-359.
28. Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96(3):988-995.
29. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariëns RA. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation. 2003;107(18):2326-2330.
30. Ajjan RA, Standeven KF, Khanbhai M, et al. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol. 2009;29(5):712-717.
31. Undas A, Topor-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn. 2009;119(6):354-359.
32. Weisel JW, Litvinov RI. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem. 2008;6(3):161-180.
33. Undas A, Stepien E, Tracz W, Szczeklik A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost. 2006;4(5):973-975.